Education
About Us
Working with TipRanks
Follow Us
Immucell Corp. (ICCC)
NASDAQ:ICCC
ICCC Stock Chart & Stats
$6.24
-$0.45(-8.32%)
At close: 4:00 PM EST
$6.24
-$0.45(-8.32%)
Day’s Range― - ―
52-Week Range$4.28 - $7.60
Previous CloseN/A
Volume9.49K
Average Volume (3M)20.75K
Market Cap
$59.43M
Enterprise Value$69.15M
Total Cash (Recent Filing)$3.89M
Total Debt (Recent Filing)$13.61M
Price to Earnings (P/E)25.4
Beta-0.29
Next Earnings
Mar 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding9,045,851
10 Day Avg. Volume22,482
30 Day Avg. Volume20,748
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)1.53
Price to Sales (P/S)1.59
P/FCF Ratio-390.09
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue2.49
Enterprise Value/Gross Profit6.08
Enterprise Value/Ebitda12.80
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Flagship Product MomentumSustained migration toward Tri‑Shield within the First Defense franchise indicates durable product adoption and customer retention in dairy and beef segments. That concentrated revenue engine supports repeat sales, distribution relationships, and scalable manufacturing leverage over the medium term.
Margin ImprovementA material gross margin improvement reflects better pricing, cost control, or product mix, improving unit economics. Higher gross margins provide structural capacity to absorb SG&A, fund R&D or sales expansion, and materially improve the path to sustainable operating profitability as volumes scale.
Free Cash Flow RecoveryA large TTM FCF increase strengthens financial flexibility to fund capacity buildouts, salesforce expansion, and working capital without heavy external financing. Improved cash generation reduces liquidity risk and supports reinvestment into the core First Defense growth strategy over the coming quarters.
Bears Say
Regulatory Setback And ImpairmentThe FDA Incomplete Letter and subsequent pause of Re‑Tain removes a meaningful product pipeline option and triggered a non‑cash impairment. This reduces future diversification, pushes commercialization risk onto partnerships/licensing, and curtails internal upside from a novel mastitis treatment.
International Sales VolatilitySharp international revenue declines highlight dependence on timing and distribution execution abroad. Persistent volatility undermines geographic diversification, magnifies revenue cyclicality, and means growth will rely more heavily on domestic channels and execution to achieve scale.
Weak Underlying ProfitabilityDespite recent quarterly improvements, very low net margin and negative EBIT indicate underlying operating leverage is limited. Structural profitability weakness constrains free cash generation, reduces resilience to demand shocks, and limits capital available for R&D or commercial expansion.
Immucell News
ICCC FAQ
What was Immucell Corp.’s price range in the past 12 months?
Immucell Corp. lowest stock price was $4.28 and its highest was $7.60 in the past 12 months.
What is Immucell Corp.’s market cap?
Immucell Corp.’s market cap is $59.43M.
When is Immucell Corp.’s upcoming earnings report date?
Immucell Corp.’s upcoming earnings report date is Mar 04, 2026 which is in 2 days.
How were Immucell Corp.’s earnings last quarter?
Immucell Corp. released its earnings results on Nov 13, 2025. The company reported -$0.015 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.015.
Is Immucell Corp. overvalued?
According to Wall Street analysts Immucell Corp.’s price is currently Overvalued.
Does Immucell Corp. pay dividends?
Immucell Corp. does not currently pay dividends.
What is Immucell Corp.’s EPS estimate?
Immucell Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immucell Corp. have?
Immucell Corp. has 9,045,851 shares outstanding.
What happened to Immucell Corp.’s price movement after its last earnings report?
Immucell Corp. reported an EPS of -$0.015 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.744%.
Which hedge fund is a major shareholder of Immucell Corp.?
Currently, no hedge funds are holding shares in ICCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immucell Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
29.72%
12-Months-Change
Fundamentals
Return on Equity
8.27%
Trailing 12-Months
Asset Growth
2.88%
Trailing 12-Months
Company Description
Immucell Corp.
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
ICCC Company Deck
ICCC Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a positive turnaround in financial performance with improved net income, gross margins, and operational efficiency. Domestic sales show positive momentum, and there is optimism surrounding the new leadership. However, challenges remain with declining total product sales and international sales, as well as inventory management concerns.View all ICCC earnings summariesTechnical Analysis
Medicinova
―
Adicet Bio
―
Werewolf Therapeutics
―
Telomir Pharmaceuticals, Inc.
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
1.65% Insiders
4.02% Mutual Funds
1.95% Other Institutional Investors
89.25% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---